Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid.

Journal of the American Heart Association·2026
Same author

Role of systemic and epicardial adipose tissue in cardiometabolic disease.

Nature reviews. Cardiology·2026
Same author

Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials.

European heart journal·2026
Same author

Lipoprotein(a) and residual cardiovascular risks in Japanese patients with coronary artery disease who achieve guideline-recommended low-density lipoprotein cholesterol goals.

European heart journal·2026
Same author

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial.

Circulation·2026
Same author

Global survey of genetic testing methods for familial hypercholesterolemia. A study and recommendations from the EAS FHSC registry.

European journal of preventive cardiology·2026
Same journal

Engineered Heart Tissues Facilitate Noncoding Variant Studies in Cardiomyopathy.

Circulation research·2026
Same journal

NUAK1 Inhibition Alleviates Ischemia-Reperfusion Injury via SYNE1-YAP1.

Circulation research·2026
Same journal

Aging Disrupts L-type Ca<sup>2+</sup> Channel Organization and Function in Pacemaker Cells.

Circulation research·2026
Same journal

Glycine Receptor α2 Mediates Vasodilation via Endothelial eNOS Signaling.

Circulation research·2026
Same journal

Antiplatelet Strategies and the Unfinished Story of Thrombosis Prophylaxis.

Circulation research·2026
Same journal

The Ugly Side of NO: Erythrocyte-Derived NO and Atherosclerosis.

Circulation research·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

CETP Inhibitors: Back With a New Target.

Stephen J Nicholls1, Kausik K Ray2, Adam J Nelson1,3

  • 1Victorian Heart Institute, Monash University, Clayton, Australia (S.J.N., A.J.N.).

Circulation Research
|June 4, 2026
PubMed
Summary
This summary is machine-generated.

Cholesteryl ester transfer protein (CETP) inhibitors show promise for reducing cardiovascular disease risk by lowering atherogenic lipids and improving glycemic control, not just by raising HDL cholesterol.

Keywords:
Alzheimer diseasecardiovascular diseasescholesteryl ester transfer proteinlipids

More Related Videos

Protein Target Prediction and Validation of Small Molecule Compound
10:21

Protein Target Prediction and Validation of Small Molecule Compound

Published on: February 23, 2024

Related Experiment Videos

Last Updated: Jun 6, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Protein Target Prediction and Validation of Small Molecule Compound
10:21

Protein Target Prediction and Validation of Small Molecule Compound

Published on: February 23, 2024

Area of Science:

  • Lipid metabolism and cardiovascular disease research.
  • Pharmacological intervention targeting CETP.
  • Neurodegenerative disease biomarker investigation.

Background:

  • Cholesteryl ester transfer protein (CETP) is crucial for lipid metabolism, with low CETP levels linked to reduced cardiovascular disease, diabetes, and neurodegeneration.
  • Previous CETP inhibitor development faced challenges including toxicity and limited efficacy.
  • Genomic studies and re-evaluation of prior programs suggest a new therapeutic pathway for CETP inhibitors.

Purpose of the Study:

  • To review the evolving understanding of CETP inhibition for therapeutic benefit.
  • To highlight the potential of selective CETP inhibitors like obicetrapib.
  • To explore applications beyond cardiovascular risk reduction, including neurodegeneration.

Main Methods:

  • Review of genetic and cohort studies on CETP function and its association with disease.
  • Analysis of outcomes from previous pharmacological CETP inhibitor development programs.
  • Examination of preclinical data for novel selective CETP inhibitors, such as obicetrapib.

Main Results:

  • Low CETP activity is associated with protection against cardiovascular disease, diabetes, and neurodegeneration.
  • Selective CETP inhibition, exemplified by obicetrapib, demonstrates favorable effects on atherogenic lipids, lipoproteins, and glycemic control.
  • Obicetrapib also shows positive impacts on biomarkers related to Alzheimer disease pathology in preclinical models.

Conclusions:

  • CETP inhibition offers a promising strategy for cardiovascular risk reduction through improved lipid profiles and glycemic control.
  • Selective CETP inhibitors represent a refined approach to drug development in this class.
  • Emerging evidence suggests broader therapeutic potential for CETP inhibition in areas like neurodegenerative diseases.